I've been following KPV research for about two years now. A few additional points:

What makes KPV special compared to full-length α-MSH is its simplicity and specificity. α-MSH has multiple biological activities — melanogenesis, anti-inflammatory, antipyretic, appetite suppression (via MC4R). The KPV tripeptide retains the anti-inflammatory activity but loses the melanocortin receptor binding. This means:

• No skin darkening/tanning effect
• No appetite effects (won't interfere with your GLP-1 RA)
• Retained anti-inflammatory mechanism via direct NF-κB inhibition

The fact that a mere tripeptide (three amino acids!) can cross cell membranes and modulate NF-κB signaling is remarkable. It's also incredibly stable for a peptide — being only three residues long, there's very little to degrade.

many GLP-1 RA users deal with GI inflammation

Exactly. And for the IBD patients on GLP-1 RAs, the standard advice of "titrate slowly and it'll get better" doesn't always apply. Their baseline gut is already compromised. KPV could be a useful adjunct in this specific population.

I have mild-to-moderate UC (diagnosed 2021, currently on mesalamine 4.8 g/day). Started semaglutide 3 months ago for weight management and have had a partial UC flare — increased frequency, some blood. My GI doc adjusted my mesalamine but I'm looking for additional options.

Is KPV something I could reasonably add? What route and dose? And would it interact with mesalamine?

First, the important caveat: you're dealing with a diagnosed IBD condition, so any additions should ideally be discussed with your GI doc. That said, I understand the reality that most GI docs won't be familiar with KPV.

On interactions: mesalamine works primarily as a topical anti-inflammatory in the colon via inhibition of prostaglandin and leukotriene synthesis (COX and LOX pathways). KPV works via NF-κB inhibition. These are different mechanisms and there's no theoretical basis for a negative interaction. If anything, they could be complementary — hitting inflammation from two different angles.

Current protocols being used in the research peptide community:

• Oral: 500-1000 mcg daily, typically in capsule form, taken on an empty stomach
• Subcutaneous: 200-500 mcg daily
• For GI-specific indications: oral route is preferred for local delivery to intestinal mucosa

The Laroui nanoparticle study is interesting because it demonstrated that oral KPV can survive the GI tract and reach the colon. As a tripeptide, it's more resistant to enzymatic degradation than larger peptides, but nanoparticle encapsulation improved colonic delivery in the mouse model.

This is interesting but how available is KPV? I haven't seen it at any of the suppliers I normally use for research peptides. Is it hard to find?